Efficiency of Using Vita-melatonin in Patients with Non-alcoholic Fatty Liver Disease in Combination with Chronic Pancreatitis and Type 2 Diabetes Mellitus
| Autor: | Yelizaveta Sirchak, Vasyl Hryha, Vasyl Barani, Oleksandra Reho |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Vitamin
medicine.medical_specialty business.industry Type 2 Diabetes Mellitus Type 2 diabetes Anthropometry medicine.disease Gastroenterology Melatonin chemistry.chemical_compound chemistry Internal medicine Nonalcoholic fatty liver disease medicine Pancreatitis Medical history business medicine.drug |
| Zdroj: | Family Medicine. :39-46 |
| ISSN: | 2412-8708 2307-5112 |
| DOI: | 10.30841/2307-5112.1.2021.231929 |
| Popis: | The objective: to analyze the effectiveness and feasibility of complex therapy with the use of a melatonin preparation in patients with nonalcoholic fatty liver disease (NAFLD) in combination with chronic pancreatitis (CP) and type 2 diabetes mellitus (DM). Materials and methods. We examined 64 patients with NAFLD in combination with CP and type 2 diabetes (mean age – 48.9 ± 5.4 years). The control group included 20 practically healthy individuals: 12 (60.0 %) men and 8 (40.0 %) women (average age – 47.6 ± 5.8 years). The patients were divided into two groups depending on the prescribed treatment: Group I (n = 30) – patients received only basic therapy (BT), Group II (n = 34) – patients were prescribed melatonin in addition to BT (Vita-melatonin, firm PJSC «Kiev Vitamin Plant», Ukraine) at a dose of 3 mg per day 30 minutes before bedtime for 1 month. All patients with NAFLD in combination with CP and type 2 diabetes before and after treatment were examined by general clinical, anthropometric, instrumental and laboratory methods. To verify the diagnosis, attention was paid to the nature of the complaints, the medical history. Results. The results of the study make it possible to recommend the melatonin preparation as part of the complex treatment of patients with NAFLD in combination with CP and type 2 diabetes due to its antioxidant, anti-inflammatory properties, as well as its ability to influence cognitive changes in these patients. Conclusion. The drug melatonin (Vita-melatonin) is an effective, safe agent for the complex treatment of patients with NAFLD in combination with CP and type 2 diabetes. Normalization of the serum melatonin level in patients with NAFLD in combination with CP and type 2 diabetes with the use of melatonin leads to a decrease and / or normalization of the indicators of cognitive status in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|